Company Filing History:
1 out of 1 
1 out of 6 
1 out of 832,912 Years Active: 2022
Title: Kyosuke Yamanishi: Innovator in Cancer Therapeutics
Introduction
Kyosuke Yamanishi is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of cancer therapeutics, particularly through his innovative patent that combines interleukin-18 (IL-18) with targeted antibodies. His work aims to enhance the effectiveness of cancer treatments.
Latest Patents
Kyosuke Yamanishi holds a patent for a therapeutic agent for cancer, which comprises a combination of IL-18 and molecule-targeting antibodies. This cancer therapeutic agent includes active ingredients such as IL-18 and one or more antibodies selected from a group that includes anti-PD-L1, anti-PD-1, anti-PD-L2, anti-CTLA-4, anti-CD25, anti-CD33, and anti-CD52 antibodies. This innovative approach has the potential to improve cancer treatment outcomes.
Career Highlights
Throughout his career, Yamanishi has worked with various organizations, including the Medical Research and Development Corporation. His dedication to advancing cancer research has positioned him as a key figure in the field.
Collaborations
Yamanishi has collaborated with notable colleagues such as Haruki Okamura and Wen Li. These partnerships have contributed to the development of his groundbreaking therapeutic agent.
Conclusion
Kyosuke Yamanishi's contributions to cancer therapeutics through his innovative patent demonstrate his commitment to improving treatment options for patients. His work continues to inspire advancements in medical research and development.